目的 :观察弥散型左旋多巴 苄丝肼 (DM )治疗帕金森病的疗效和安全性。方法 :采用全国多中心、开放性试验 ,给原用标准片左旋多巴 苄丝肼的 2 0 4例帕金森病病人 ,根据伴随症状的不同 ,选用不同的弥散型左旋多巴 苄丝肼治疗共 8wk。通过Webster评分、病人日记和实验室检查评价药物疗效和安全性。结果 :由标准片左旋多巴 苄丝肼改用或加用弥散型左旋多巴 苄丝肼后 ,“开”期潜伏期缩短 37min ,“开”期持续时间增加 4 7min ,“关”期减少 11min ,Webster评分改善 2 5% ,P <0 .0 1。不良反应少。结论 :弥散型左旋多巴 苄丝肼是一种快速有效和安全的抗帕金森病药物新剂型 ,尤适用于晨僵、“开”期延迟、午后“关闭”、吞咽困难等帕金森病病人 Objective: To observe the efficacy and safety of diffuse levodopa and benserazide in the treatment of Parkinson’s disease. METHODS: A nationwide multicenter, open-label trial was used to treat 240 patients with Parkinson’s disease who were treated with benidrazole, a standard prophylaxis, and treated with benignised levodopa according to the accompanying symptoms Total 8wk. Drug efficacy and safety were evaluated by Webster score, patient diary and laboratory tests. Results: After the standard tablets of levodopa and benserazide were used or added, the incubation period of “on” period was shortened 37min, the duration of “on” period was increased 47min and the period of “off” was reduced 11min Webster’s score improved by 25%, P <0. Adverse reactions. CONCLUSIONS: Diffuse levodopa and benserazide is a fast, effective and safe new dosage form for anti-Parkinson’s disease. It is especially suitable for Parkinson’s disease patients with morning stiffness, delayed “on” phase, “closed” in the afternoon and dysphagia.